Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of IMC-F106C, a PRAME Targeted ImmTAC, in Rare Cancers

NCT07686367 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT07686367
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07686367 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of IMC-F106C, a PRAME Targeted ImmTAC, in Rare Cancers
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 23, 2026
Completion date
November 30, 2027
Enrollment
42 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic myxoid liposarcoma, metastatic synovial sarcoma, unresectable myxoid liposarcoma, unresectable synovial sarcoma